The iPSC Workshop on human iPSC derivation, maintenance, differentiation and CRISPR/Cas9 gene editing, organized by Wenli Yang, was held May 14 – 18, 2018 at the iPSC Core laboratory of the Penn Institute for Regenerative Medicine. This week-long course was comprised of Penn faculty lectures, in-depth technical lectures by Core staff, and hands-on learning in the iPSC Core facility. While the lecture portion was open to University trainees, staff, and faculty, the hands-on experience was reserved for 10 students to allow for a more immersive education, which they do not have access to in their own institutions. The students came from around the world, were of varying ages and educational backgrounds, and were in different stages of their careers. This course offered them a strong iPSC foundation to build upon as well as the opportunity to network with scientists and researchers.

The course was a success, and Wenli is excited to offer it again in spring 2019. More details to follow this upcoming winter.

The iPSC Core and the Penn IRM are committed to providing pluripotent stem cell culture resources to the research community.  We welcome collaborative and interdisciplinary opportunities across departments, schools, and external institutions.  Please don’t hesitate to reach out to us.

About Dr. Wenli Yang:

Dr. Wenli Yang came to the University of Pennsylvania in October 2009 to establish the human induced Pluripotent Stem Cell (iPSC) Core facility within the Institute for Regenerative Medicine. She is currently Research Assistant Professor of Medicine and the co-director of the iPSC Core, which serves the Penn and external research communities in pluripotent stem cell culture, iPSC derivation and differentiation of PSCs to various cell lineages, PSC genome engineering using CRISPR/Cas9, and training University staff in these technologies. Using these research tools, Dr. Yang is engaged in collaborative research programs in the areas of lung regeneration, hepatocyte gene expression, adipocyte biology, and cardiomyocyte biology, as well as developing methods for generation and maturation of iPSC-derived cell lineages. Dr. Yang obtained her Ph.D. in molecular genetics from the University of California, Los Angeles, where she studied the role of lipid modifications in small G-protein signaling in the fission yeast. After obtaining her Ph.D., she trained as a postdoctoral fellow with Dr. Bruce Spiegelman at Harvard Medical School where she focused on molecular mechanisms of adipocyte development and function. Before coming to UPenn, Dr. Yang was a senior scientist at Syndexa Pharmaceuticals Corp. in Cambridge, MA where she led efforts in metabolic disease drug discovery.